NO2665471T3 - - Google Patents

Info

Publication number
NO2665471T3
NO2665471T3 NO12736469A NO12736469A NO2665471T3 NO 2665471 T3 NO2665471 T3 NO 2665471T3 NO 12736469 A NO12736469 A NO 12736469A NO 12736469 A NO12736469 A NO 12736469A NO 2665471 T3 NO2665471 T3 NO 2665471T3
Authority
NO
Norway
Application number
NO12736469A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2665471T3 publication Critical patent/NO2665471T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/13Amines containing three or more amino groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10Hydrazines
    • C07C243/12Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
    • C07C243/16Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/04Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/10Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C07C251/12Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton being acyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72Hydrazones
    • C07C251/74Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/78Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
NO12736469A 2011-01-19 2012-01-19 NO2665471T3 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161434269P 2011-01-19 2011-01-19

Publications (1)

Publication Number Publication Date
NO2665471T3 true NO2665471T3 (fr) 2018-05-26

Family

ID=46516367

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12736469A NO2665471T3 (fr) 2011-01-19 2012-01-19

Country Status (10)

Country Link
US (4) US8858991B2 (fr)
EP (1) EP2665471B1 (fr)
CA (1) CA2825014C (fr)
DK (1) DK2665471T3 (fr)
ES (1) ES2662373T3 (fr)
HU (1) HUE038543T2 (fr)
NO (1) NO2665471T3 (fr)
PL (1) PL2665471T3 (fr)
PT (1) PT2665471T (fr)
WO (1) WO2012100043A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627676T3 (es) 2007-03-09 2017-07-31 Pathologica Llc MGBG para la regulación de osteopontina y el tratamiento de la esclerosis múltiple
NZ628513A (en) 2009-07-16 2016-01-29 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
US9675566B2 (en) * 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
EP2665471B1 (fr) 2011-01-19 2017-12-27 Pathologica, LLC. Formes posologiques pharmaceutiques orales à libération contrôlée comprenant de la mgbg
CN105163730B (zh) 2013-01-08 2018-10-30 帕萨罗杰卡有限公司 用于治疗脱髓鞘疾病的方法和组合物
US10987368B2 (en) * 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201788A (en) 1976-10-20 1980-05-06 University Patents, Inc. Process for alleviating proliferative skin diseases
US5614557A (en) 1977-07-11 1997-03-25 Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. Method of controlling tumor growth rate
US4520031A (en) * 1981-06-01 1985-05-28 The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Method for reducing toxic effects of methyl-glyoxal bis-guanylhydrazone
CA1338366C (fr) 1984-12-26 1996-06-04 Algis Anilionis Systeme d'expression procaryotique d'une grande efficacite
US5580715A (en) 1994-08-05 1996-12-03 The Regents Of The University Of California Diagnosis of cancer having clonal macrophage involvement
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US5698563A (en) 1995-01-13 1997-12-16 Alteon Inc. Bis- hydrazones!
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
US6169115B1 (en) 1998-05-22 2001-01-02 Rima Kaddurah-Daouk Use of aminoguanidine analogs for the treatment of diseases of the nervous system
US6544541B1 (en) 1999-06-02 2003-04-08 Cardiovascular Solutions, Inc. Devices and compounds for treating arterial restenosis
WO2001060392A1 (fr) 2000-02-18 2001-08-23 Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science Formes posologiques a administration par voie orale, nasale et pulmonaire du copolymere 1
US7754765B2 (en) 2000-12-01 2010-07-13 Radical Vision Therapeutics Inc Copper chelators for treating ocular inflammation
US6991809B2 (en) * 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
WO2003016491A2 (fr) 2001-08-15 2003-02-27 The Regents Of The University Of California Retrovirus isole a partir d'histiocytes de cellules du manteau
US7030126B2 (en) 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
US7622117B2 (en) 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
EP1389480A1 (fr) 2002-08-14 2004-02-18 Mondobiotech Interferon SA Utilisation thérapeutique de guanylhydrazones pour l'inhibition des procédés dépendant du CD83 et de la maturation des cellules dendritiques
EP1613263A4 (fr) 2003-01-31 2007-11-28 Pathologica Llc Suivi et de traitement de la sclerose laterale amyotrophique
US20060177506A1 (en) * 2003-03-17 2006-08-10 Shigeo Yanai Release control compositions
HUE028247T2 (en) 2003-04-08 2016-12-28 Novartis Ag A solid oral composition comprising S1P receptor agonist and sugar alcohol
RU2375048C2 (ru) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
WO2005041988A1 (fr) 2003-10-22 2005-05-12 University Of Florida Procédé et composition de soulagement de la douleur
US7445794B1 (en) * 2004-04-29 2008-11-04 The Regents Of The University Of Colorado Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors
KR20070110046A (ko) 2005-01-28 2007-11-15 크산투스 파마슈티컬스, 인코포레이티드 염증 및 탈수초성 질환을 치료하기 위한 화합물
AU2006275679B2 (en) 2005-07-29 2012-04-12 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of Chk2 kinase inhibitors for cancer treatment
JP2009502908A (ja) * 2005-07-29 2009-01-29 スティッチング グロニンゲン セントル フォー ドラッグ リサーチ pH制御パルス送達システム、その調製法及び使用法
CN101300004B (zh) 2005-09-23 2013-08-21 帕瑟洛吉卡有限公司 使用多胺类似物治疗病毒感染的方法
US20070202515A1 (en) * 2005-10-12 2007-08-30 Pathologica, Llc. Promac signature application
US20110091418A1 (en) 2006-09-25 2011-04-21 Pathlogica, LLC Methods for treating viral infections using polyamine analogs
EP2164698A1 (fr) 2007-03-09 2010-03-24 Sustainable Solutions, Inc. Matériau de panneau en coton régénéré et procédé de fabrication
ES2627676T3 (es) 2007-03-09 2017-07-31 Pathologica Llc MGBG para la regulación de osteopontina y el tratamiento de la esclerosis múltiple
NZ580972A (en) * 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
WO2009018368A1 (fr) 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Traitement d'association à base d'amplificateur du nmda (n-méthyl-d-aspartate), d'inhibiteur de transporteur de glycine, d'inhibiteur de d-amino acide oxydase pour des troubles neuropsychiatriques
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
JP2012505257A (ja) 2008-10-13 2012-03-01 バイオヴィスタ,インコーポレイテッド 多発性硬化症治療のための組成物および方法
WO2010066203A1 (fr) * 2008-12-10 2010-06-17 Anhui Zhongren Technology Co., Ltd. Composition à libération contrôlée
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
NZ628513A (en) 2009-07-16 2016-01-29 Pathologica Llc Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
EP2283830A1 (fr) * 2009-07-23 2011-02-16 Actogenix N.V. Revêtement de capsule entérique aqueuse
EP2343075A1 (fr) 2010-01-04 2011-07-13 Neurotec Pharma, S.L. Diazoxyde à utiliser dans le traitement d'une maladie de démyélinisation auto-immune du système nerveux central (SNC)
TWI590821B (zh) * 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
EP2665471B1 (fr) 2011-01-19 2017-12-27 Pathologica, LLC. Formes posologiques pharmaceutiques orales à libération contrôlée comprenant de la mgbg
CN105163730B (zh) 2013-01-08 2018-10-30 帕萨罗杰卡有限公司 用于治疗脱髓鞘疾病的方法和组合物

Also Published As

Publication number Publication date
HUE038543T2 (hu) 2018-10-29
CA2825014A1 (fr) 2012-07-26
US10881626B2 (en) 2021-01-05
CA2825014C (fr) 2019-01-08
US20120269891A1 (en) 2012-10-25
PT2665471T (pt) 2018-03-21
US9668988B2 (en) 2017-06-06
ES2662373T3 (es) 2018-04-06
PL2665471T3 (pl) 2018-06-29
EP2665471B1 (fr) 2017-12-27
US8858991B2 (en) 2014-10-14
WO2012100043A2 (fr) 2012-07-26
EP2665471A2 (fr) 2013-11-27
WO2012100043A3 (fr) 2012-10-18
DK2665471T3 (en) 2018-03-19
EP2665471A4 (fr) 2014-07-23
US20180050000A1 (en) 2018-02-22
US20140377345A1 (en) 2014-12-25
US20210085625A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
BR112013022641A2 (fr)
BR112013031251A2 (fr)
BR112013027245A2 (fr)
BR112013024383A2 (fr)
BR112013026905A2 (fr)
BR112013023185A2 (fr)
BR112013022995A2 (fr)
BR112013017670A2 (fr)
BR112013026744A2 (fr)
BR112013023927A2 (fr)
BR112013027830A2 (fr)
BR112013024365A2 (fr)
BR112013027121A2 (fr)
BR112013027452A2 (fr)
BR112013031556A2 (fr)
BR112013026790A2 (fr)
BR112013024588A2 (fr)
BR112013032380A2 (fr)
BR112013032377A2 (fr)
BR112013032366A2 (fr)
BR112013018949A2 (fr)
BR112013027761A2 (fr)
BR112013021637A2 (fr)
BR112013027836A2 (fr)
BR112013023266A2 (fr)